E N D
Figure 1 Approved or in-trial antibody-based and receptor-based biologic agents (in red) targeting either primary cells (B cells, T cells, macrophages, endothelial cells, osteoclasts and fibroblasts) and/or the circulating mediators (TNF, IL-15, VEGF, RANKL, BLyS, CD80/CD86) involved in rheumatic diseases Rothe A et al. (2008) Therapeutic advances in rheumatology with the use of recombinant proteins Nat Clin Pract Rheumatol doi:10.1038/ncprheum0909